Do open label blinded outcome studies of novel anticoagulants versus warfarin have equivalent validity to those carried out under double-blind conditions?
- 1 January 2013
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 109 (03), 497-503
- https://doi.org/10.1160/th12-10-0715
Abstract
Recent anticoagulants for stroke prevention in AF have been tested in active comparator controlled studies versus warfarin using two designs: double-blind, double-dummy and prospective randomised, open blinded endpoint (PROBE). The former requires elaborate procedures to maintain blinding, while PROBE does not. Outcomes of double-blind and PROBE designed studies of novel anticoagulants for AF, focusing on warfarin controls, were explored. Major, Phase III warfarin-controlled trials for stroke prevention in AF were identified. Odds ratios (ORs) of key outcomes for active comparators versus VKA and event rates for VKA arms were compared between designs, in context of baseline demographics and inclusion criteria. Identified trials studied five novel anticoagulants in three each of PROBE and double-blind design. For ORs of results across studies and outcomes, there was little pattern differentiating the two designs. Among VKA-control subjects, event rates for the primary outcome (stroke or systemic embolism) in PROBE trials at 1.74 %/year (95% confidence interval: 1.54–1.95) was not significantly different from that in double-blind trials, at 1.88 (1.73–2.03). Among other outcomes, VKA-treated subjects in both trial designs had similar event rates, apart from higher all-cause mortality in ROCKET AF, and lower myocardial infarction rates among the PROBE study patients. Although there are differences in outcome between PROBE and double blind trials, they do not appear to be design-related. The exacting requirements of double-blinding in AF trials may not be necessary.Keywords
Funding Information
- Boehringer Ingelheim
This publication has 23 references indexed in Scilit:
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Ischaemic stroke and bleeding rates in ‘real-world’ atrial fibrillation patientsThrombosis and Haemostasis, 2011
- What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?Thrombosis and Haemostasis, 2011
- Newly Identified Events in the RE-LY TrialNew England Journal of Medicine, 2010
- Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)European Heart Journal, 2010
- Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulantsJournal of Thrombosis and Haemostasis, 2008
- Open-label trials and drug registration: a European regulator’s viewJournal of Thrombosis and Haemostasis, 2008
- The statin warsThe Lancet, 2003
- Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V)American Heart Journal, 2003
- Prospective Randomized Open Blinded End-point (PROBE) Study. A novel design for intervention trialsBlood Pressure, 1992